NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 37 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $11,929 | +18.6% | 14,372 | 0.0% | 0.00% | – |
| Q1 2023 | $10,060 | +37.5% | 14,372 | 0.0% | 0.00% | – |
| Q4 2022 | $7,315 | -18.7% | 14,372 | 0.0% | 0.00% | – |
| Q3 2022 | $9,000 | -40.0% | 14,372 | -0.6% | 0.00% | – |
| Q2 2022 | $15,000 | -93.1% | 14,457 | -87.5% | 0.00% | – |
| Q1 2022 | $218,000 | -61.8% | 116,026 | -1.8% | 0.00% | – |
| Q4 2021 | $570,000 | -35.7% | 118,152 | -3.8% | 0.00% | – |
| Q3 2021 | $887,000 | -16.6% | 122,766 | +6.6% | 0.00% | – |
| Q2 2021 | $1,063,000 | -25.4% | 115,142 | -0.5% | 0.00% | – |
| Q1 2021 | $1,425,000 | -15.2% | 115,747 | -3.0% | 0.00% | – |
| Q4 2020 | $1,681,000 | +25.8% | 119,275 | +7.1% | 0.00% | – |
| Q3 2020 | $1,336,000 | -31.5% | 111,347 | -5.2% | 0.00% | -100.0% |
| Q2 2020 | $1,950,000 | +652.9% | 117,497 | +415.9% | 0.00% | – |
| Q1 2020 | $259,000 | +32.8% | 22,775 | +43.5% | 0.00% | – |
| Q4 2019 | $195,000 | +314.9% | 15,866 | -3.7% | 0.00% | – |
| Q3 2019 | $47,000 | – | 16,478 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 810,073 | $9,980,000 | 6.05% |
| EcoR1 Capital, LLC | 3,915,880 | $48,244,000 | 4.35% |
| Opaleye Management Inc. | 1,381,300 | $17,018,000 | 3.34% |
| Avidity Partners Management LP | 210,000 | $2,587,000 | 1.63% |
| ACUTA CAPITAL PARTNERS, LLC | 372,500 | $4,589,000 | 1.14% |
| Boxer Capital, LLC | 1,009,255 | $12,434,000 | 0.70% |
| Redmile Group, LLC | 1,920,831 | $23,665,000 | 0.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 379,998 | $4,682,000 | 0.39% |
| Sio Capital Management, LLC | 88,185 | $1,086,000 | 0.26% |
| Baker Brothers Advisors | 3,397,740 | $41,860,000 | 0.22% |